Evidence map›Paper›PMID 42517548›Full record

Trial reportHIV medicine2026

Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.

Jordan E Lake, Douglas W Kitch, Amy Kantor, Rebeca Mayo, Pablo Belaunzaran-Zamudio, Carl J Fichtenbaum, Todd T Brown, Kathleen E Corey, Fred Sattler, Kristine M Erlandson

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jordan E LakeDepartment of Internal Medicine, UTHealth Houston, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-0640-5514
Douglas W KitchCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0001-7999-8912
Amy KantorCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Rebeca MayoRubió Metabolomics, Derio, Spain.
Pablo Belaunzaran-ZamudioNational Institute of Allergy and Infectious Diseases (NIAID), Rockville, Maryland, USA.ORCID https://orcid.org/0000-0003-4775-4734
Carl J FichtenbaumDepartment of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-6778-7253
Todd T BrownDepartment of Internal Medicine, Johns Hopkins University, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-8599-278X
Kathleen E CoreyDepartment of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Fred SattlerDepartment of Internal Medicine, University of Southern California, Los Angeles, California, USA.
Kristine M ErlandsonDepartment of Internal Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID https://orcid.org/0000-0003-0808-6729

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI106701NIH HHS UM1 AI068634NIH HHS UM1 AI068636NIH HHS UM1 AI106701UTHealth Houston
6 · The paper itself

Abstract

objectivesWe have shown that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is a highly effective therapy for metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV (PWH). The OWLiver® metabolomics algorithms allow non-invasive MASLD severity staging without liver biopsy, but the use of metabolomic data for disease monitoring with GLP-1RA therapy has not been reported.

methodsSLIM LIVER (ACTG A5371) was an open-label, phase 2b, single-arm trial of semaglutide in PWH and MASLD (2021-2022). Adult participants who showed clinical response (>2.27 kg weight loss) to semaglutide during the study (N = 36) had their serum analysed for metabolomic profiling by the OWLiver® panel.

resultsTwenty-four weeks of low-dose semaglutide led to significant improvement in MASLD disease severity by serum metabolomic profiling across all MASLD disease severity categories, suggesting histologic improvements.

conclusionsThe OWLiver® metabolomics algorithms can be used to monitor MASLD severity during GLP-1RA therapy.

Indexed as

Fatty LiverGlucagon-Like Peptide-1 Receptor AgonistsHIV InfectionsSemaglutideAdultFemaleHumansLiverMaleMetabolomicsMiddle AgedSeverity of Illness IndexTreatment OutcomeGlucagon-Like Peptide-1 Receptor AgonistsSemaglutideHIVmetabolic dysfunction‐associated steatotic liver diseasesemaglutide

Identifiers

PMID42517548
PMCPMC13631692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.